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To determine the outcome of patients with metastatic malignant melanoma (MMM) treated with palliative whole brain radiotherapy
(WBRT) and to identify factors that predict treatment outcome to assist future trial design, a retrospective study was performed on
patients with MMM who received WBRT at the Royal Marsden Hospital between 1998 and 2003. Data regarding patient factors,
tumour factors and survival were collected. A total of 112 patients were identified and full data were available for 102 patients. The
median age was 53 years (range 25–81 years), 66.7% were male and 33.3% female. The median dose prescribed was 20Gy in five
fractions as a mid-plane dose. The median survival after WBRT for the whole group was 51 days (range 3–1386). In an attempt to
define prognostic groups, we used the validated RTOG recursive partitioning analysis (RPA) classification for brain metastasis (class 1:
Karnofsky Performance Score (KPS) X70%, age o65 years with no extracranial metastasis; class 3: KPS o70%; class 2: all others).
The median survivals were 151, 71 and 21 days for RPA class 1, 2 and 3, respectively (Po0.001). Multivariate analysis showed that
RPA class, leptomeningeal involvement, presence and number of extracranial metastatic sites and progressive disease in the brain on
imaging before WBRT are important independent predictive factors. A prognostic index was derived from these factors that allowed
identification of patients unlikely to benefit from WBRT. In conclusion, the RTOG RPA classification is valid when applied to patients
with MMM. Patients in RPA class 1 and good prognosis class 2 are likely to benefit from palliative WBRT and should be considered
for entry into trials that aim to improve duration of response. We identified that patients with RPA class 3, leptomeningeal
involvement or RPA class 2 with poor prognostic index are unlikely to benefit from palliative WBRT.
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Brain metastases are a frequent development in the natural history
of metastatic malignant melanoma (MMM). They present clinically
in 8–46% of patients and are found at autopsy in 55–75% (Amer
et al, 1978; Patel et al, 1978; Bullard et al, 1981). The prognosis is
measured in months and the aim of treatment is palliative. The
optimum role of surgery, stereotactic radiotherapy (SRT) and
whole brain radiotherapy (WBRT) remains undefined and
controversial.
Surgery and SRT may be used when disease is limited to less
than three lesions. Many studies show improved survival in those
undergoing resection and also in those with no extracranial
metastases (Katz 1981; Madajewicz et al, 1984; Choi et al, 1985;
Ziegler and Cooper 1986; Skibber et al, 1996; Ellerhorst et al, 2001).
A series of 91 patients undergoing surgical resection of MMM
brain metastases showed that the outcome was better if the patient
had no neurological deficit, a single supratentorial site and no lung
or visceral metastases. It also showed no benefit to adding WBRT
with a median survival of 9.5 months with WBRT and 8.3 months
without (Wronski and Arbit, 2000). A study of 122 patients treated
with gamma knife radiosurgery showed a median survival of 7
months with improved survival and freedom from tumour
progression in those with tumours o3cm and inactive systemic
disease. It also showed no benefit of WBRT in multivariate analysis
(Yu et al, 2002). It must be remembered that the patients selected
for surgery or SRT are those with a low disease burden and good
performance status who are likely to benefit from a more
favourable natural history of their malignancy.
Whole brain radiotherapy is commonly used for palliation for
patients with large or multiple metastases. It has been shown to
provide symptomatic improvement in 76% of patients (Carella
et al, 1980). It is most commonly combined with corticosteroid
therapy, which is discontinued on completion of WBRT and
resolution of symptoms. The largest reported series of WBRT in
MMM is by Sampson et al (1998) who treated 180 patients with a
median survival of 120 days. Other smaller series report similar
median survivals in the range of 9–20 weeks (Madajewicz et al,
1984; Choi et al, 1985; Ziegler and Cooper, 1986; Barth et al, 1995;
Gupta et al, 1997; Ellerhorst et al, 2001). Numerous studies of the
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leffects of fraction size on palliation and survival have failed to
demonstrate a survival advantage and many authors recommend a
total dose of at least 30Gy (Ellerhorst et al, 2001). We currently
recommend a dose of 20Gy in five fractions over 1 week.
The role of systemic agents with the ability to cross the blood–
brain barrier has been investigated. Drugs such as fotemustine and
temozolomide have reported single-agent response rates of 25%
(Douglas and Margolin, 2002). They are currently being studied in
combination with WBRT. A study of temozolomide with WBRT for
MMM in 31 patients has shown a median survival of 6 months, a
CR in only one patient and PR in only two patients leading the
authors to conclude that WBRT has a lower than expected activity
(Margolin et al, 2002). A recent French randomised phase III trial
in 76 patients showed that fotemustine plus WBRT delayed the
time to brain tumour progression compared to fotemustine alone,
but without significant improvement in terms of objective control
or overall survival (Mornex et al, 2003).
As a background to designing future studies of palliative WBRT
in patients with brain metastases from MMM, we have conducted a
retrospective review of patients treated at the Royal Marsden
Hospital in the last 5 years. The focus of this work was an attempt
to define patient- and disease-related characteristics predictive of
treatment outcome. As a starting point for this analysis, the RTOG
recursive partitioning analysis (RPA) classification of brain
metastasis that has been validated in lung and breast cancer
patients (Gasper et al, 2000) was applied to this group of patients.
PATIENTS AND METHODS
The Royal Marsden Hospital database was searched for patients
with MMM who received WBRT between January 1998 and June
2003. A total of 112 patients were identified and their case notes
and radiotherapy records were reviewed. Data were collected
regarding patient factors, tumour factors, treatment and survival.
We contacted the general practitioners of patients lost to follow-up
to obtain further information.
Information was collected on the patient demographics, date of
diagnosis of melanoma, date of diagnosis of brain metastases
(taken as the date of the diagnostic CT or MRI scan), local and
systemic disease status, date of completion of WBRT and the date
of death or last follow-up. The cause of death was recorded if
available. The radiotherapy dose and schedule were recorded. The
indications for WBRT were stratified as follows: symptoms
(headache, nausea and vomiting), fits, neurological deficit, post-
operative radiotherapy, asymptomatic progression and progressive
disease on imaging (carried out to investigate progressive
neurological symptoms or as part of a staging scan to assess
response to systemic therapy). The number of brain metastases
and the presence or absence of leptomeningeal involvement on
imaging were recorded. From the notes and imaging reports, we
recorded the presence and sites of extracranial metastases and if
the disease was stable or progressing. Any response in the brain
following WBRT on imaging was noted, although this parameter
was only assessed in a small number of patients. The details of all
prior chemotherapy, surgery and SRT were recorded.
Because of the retrospective nature of this study, no data were
available on the palliative benefit of WBRT. The symptomatic
benefit of WBRT has been studied, and separating the relative
benefits of steroids and radiotherapy is difficult. If patients survive
long enough, they will obtain a symptomatic benefit from WBRT
in up to 76% of cases (Carella et al, 1980). Our aim with this review
was to identify factors predicting a poor outcome and to help
identify those who are unlikely to survive long enough to see a
palliative benefit.
To use the RTOG RPA classification data on age, extracranial
metastasis and Karnofsky Performance Status (KPS) were needed
(Gasper et al, 2000). We then assigned RPA class 1 to those with
KPS X70%, age less than 65 years with controlled primary and no
extracranial metastasis, RPA class 3 to those with KPS o70% and
RPA class 2 to all others (i.e. KPS X70%, age X65 years,
uncontrolled primary or evidence of extracranial metastases). The
KPS was not formally recorded prospectively in the majority of
cases, but it was relatively easy to determine from the detailed case
note entries prior to commencement of WBRT if the KPS was X70
or o70%. In cases with insufficient information in the case notes,
an RPA class was not assigned.
Radiotherapy technique and delivery
Whole brain radiotherapy was delivered to all patients using a
thermoplastic or Perspex immobilisation shell. All the brain tissue
above a baseline extending from the supraorbital ridge to the
external auditory meatus was treated with parallel-opposed lateral
fields with the dose prescribed at the mid-plane. Treatment was
delivered using a
60Co source or a 6MV linear accelerator in all
cases.
Statistical analysis
The median survival after WBRT was calculated from the date of
completion of radiotherapy to the date of death or the date of last
follow-up in those still alive at the time of analysis. The Kaplan–
Meier method was used to plot survival curves and the log-rank
test was used to analyse differences between groups. Data analysis
was performed using an SPSS statistics program. Univariate and
multivariate analyses were performed and a prognostic index was
formulated.
RESULTS
Patient characteristics
In the time period of the study, 112 patients were treated with
WBRT for MMM. Complete survival and follow-up data were
available on 102 patients. We excluded 10 patients for whom we
could not obtain follow-up details. The data analysed were
incomplete in 23 patients. Of these, data were incomplete on
extracranial metastases in six, on the number of brain metastases
in four, on whether the brain metastasis has progressed on CT
imaging in 20 and in four patients it was not possible to assign an
RPA class due to insufficient information.
The median age of the patients was 53 years (range 25–81
years), 68 were male and 34 female. The median time from
diagnosis of melanoma to diagnosis of brain metastasis was 976
days (range 0–4808 days). Four patients had brain metastasis at
presentation, and 77 patients had extracranial disease that was
stable in 38 patients and progressive in 39 patients. The number
and sites of extracranial metastases were recorded and are shown
in Table 1. In all, 18 patients had a single brain metastasis, 15 two
metastases and 61 multiple (X3) metastases. The indications for
WBRT were symptoms in 72 patients, fits in three patients,
neurological deficit in 41 patients, postoperative radiotherapy in
seven patients and progressive disease (PD) in the brain on
imaging (CT or MRI) in 28 patients. Only two patients receiving
WBRT had asymptomatic progressive intracranial disease.
Treatment
All 102 patients received WBRT at the Royal Marsden Hospital
with either a
60Co teletherapy source or a 6MV linear accelerator.
A range of doses was used as follows: 20Gy in five fractions – 76
patients; 30Gy in 10 fractions – seven patients; 24Gy in six
fractions – five patients; 30Gy in six fractions – three patients;
other fraction schedules – three patients; failed to complete
radiotherapy – eight patients.
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and five patients had had prior surgery for brain metastases with
WBRT given at the time of disease progression. Two patients had
received prior SRT and four patients had SRT after WBRT on
progression. In all, 46 patients had received prior chemotherapy
(one regimen (35 patients), two regimens (seven patients), three
regimens (two patients), four regimens (two patients)), 15 patients
received initial chemotherapy (fotemustine (seven patients),
temozolomide (five patients), DTIC (one patient), interferon-a
(one patient), a phase 1 drug (one patient)) for brain metastasis
with WBRT delivered at the time of progression, and 12 patients
had received prior adjuvant interferon-a.
Survival
At the time of data analysis, five patients were still alive. The cause
of death was recorded as metastatic melanoma in 71 patients and
cerebrovascular accident in one patient. We were unable to
determine if death was due to intracerebral or extracranial disease
in all but a few patients. The certified cause of death was unknown
in 25 patients.
Of the 102 patients, 24 had CT imaging to assess response after
WBRT. Response data were recorded according to the WHO
criteria. Four patients had evidence of radiological partial response
and eight patients had a minor response (o50% reduction). One
patient had stable disease and 11 had evidence of disease
progression.
The median survival after WBRT for the whole group was 51
days (95% CI 34–68, range 3–1386) (see Figure 1). Using the
RTOG RPA classification for brain metastases, there was a
significant difference in survival between the classes (see
Figure 2). Class 1 had a median survival of 151 days (95% CI
78–224, range 42–288), class 2 a median survival of 71 days (95%
CI 45–97, range 13–1386) and class 3 a median survival of 21 days
(95% CI 2–40, range 3–171) (Po0.001). Patients with no
extracranial metastases had a median survival of 105 days (range
4–335 days) and those with extracranial metastases had a median
survival of 39 days (range 3–1386 days) (P¼0.016). In patients
with extracranial metastases, those with stable disease (n¼38)
survived a median 40 days (range 13–1386 days) and those with
progressive disease (n¼39) survived a median 39 days (range 8–
368 days). Seven patients had leptomeningeal involvement on
imaging and had a median survival post-WBRT of 23 days (range
3–63 days) (P¼0.003). Eight patients did not complete the
prescribed course of WBRT due to clinical deterioration and had a
median survival of 7 days (range 3–9 days).
The results of univariate and multivariate analyses are shown in
Tables 2 and 3, respectively. The multivariate model implies that
RPA, meningeal involvement, number of extracranial metastatic
sites and progressive disease in the brain on imaging are important
independent predictive factors. A prognostic index summarising
the contribution of each of these factors to prognosis was
calculated by creating a single score summarising the relative
contribution of each factor (Table 4). The prognostic score was
calculated using the formula prognostic score¼(number of ECM
sitesþ(2 RPA)þ(2 if PD in brain on imaging)þ(4 if leptome-
ningeal involvement)).
Table 1 Patient characteristics
Number
Gender M¼68, F¼34
Age (years) 53 (median)
Indications for WBRT
Symptoms 72
Fits 3
Neurology 41
Postoperative 7
Asymptomatic PD in brain 2
PD in brain on imaging 28
Extra-cranial metastasis 77
Stable disease 38
Progressive disease 39
Number of metastatic sites
12 0
22 8
31 5
48
54
NK 2
Site of metastasis
Liver 24
Lung 52
Lymph nodes 50
Soft tissue/subcutaneous 18
Spleen 9
Adrenal 12
Other 18
Number of brain metastasis
11 8
21 5
Multiple (X3) 61
NK 8
RPA class
11 4
25 4
33 0
NK 4
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Figure 1 Overall survival of 102 patients with cerebral metastases from
malignant melanoma.
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RPA 1
RPA 2
RPA 3
RPA 1  N = 14  O = 11 E = 20.0
RPA 2  N = 54  O = 52 E = 61.8
RPA 3  N = 30  O = 30 E = 11.2
ψ2 = 36.86  df = 2  P <0.00001 
Figure 2 Survival according to RPA class.
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sized groups and its performance examined. Prognostic indices
inevitably perform well if they are both derived and tested on the
same set of data, so strictly this index still requires external
validation. However, taking as the starting point that RPA class 1
patients should be treated and those that are class 3 should not be
treated, the index enables the intermediate group (class 2) to be
split into those that should and should not be treated. If the score
number of other sitesþ2 (if progressive disease in brain on
imaging)þ4 (if leptomeningeal involvement) is 5 or greater, then
patients would only be expected to have a median survival of 21
days or less.
It is noteworthy that progressive disease on imaging before
starting WBRT was a significant prognostic variable on multi-
variate, but not on univariate, analysis. This apparent anomaly is
probably accounted for by the fact that showing progressive
disease on a CT or MRI scan is inversely correlated with RPA, the
most highly predictive single factor. The proportions showing
progressive disease on imaging prior to WBRT in the three RPA
groups were 54% (class 1, n¼13), 40% (class 2, n¼43) and 15%
(class 3, n¼22). The relatively high proportion of good prognosis
patients with progressive disease on imaging prior to WBRT is
likely to be the reason as to why it was not significant on univariate
analysis. However, within the RPA classes, the patients with
progressive disease on imaging prior to WBRT have a worse
outcome. For example, in a Cox model with RPA and progressive
disease on imaging prior to WBRT as factors, the latter has a
hazard ratio of 2.2 (P¼0.01).
For the patients who had a documented partial or minor
response on CT imaging after WBRT, three patients were in RPA
class 1 and nine were in RPA class 2. Nine of the patients received
radiation doses of 20Gy in five fractions. The median prognostic
index scores were 6.5 (range 5–7) for those with a partial response
and 4.5 (range 2–7) for those with a minor response.
DISCUSSION
This retrospective review confirms the data from other studies that
patients with brain metastases from MMM have a very poor
prognosis. The median overall survival of approximately 7 weeks is
similar to that quoted by other authors who have reported median
survivals of between 9 and 20 weeks (Madajewicz et al, 1984; Choi
et al, 1985; Ziegler and Cooper, 1986; Barth et al, 1995; Gupta et al,
1997; Ellerhorst et al, 2001). Clearly, in a situation with such a poor
prognosis, it is important to attempt to deliver treatment
according to rational guidelines based on the likelihood of gaining
a palliative benefit. Ideally, patients with little or no prospect of
clinical benefit could be identified and offered best supportive care
and those with a better prognosis could be offered active
treatment.
To this end, the data presented here have shown that the RTOG
RPA classification is valid when applied to MMM and facilitates
the effective separation of patients into different prognostic groups
(Figure 3). In particular, this approach is successful in identifying
patients with a very poor outcome following WBRT. Patients in
RPA class 3 and those with leptomeningeal disease were found to
have the worst prognosis with a median survival of only 3 weeks.
This group of patients should not receive palliative WBRT but,
rather, should be treated with best supportive care alone. Similarly,
the presence of extracranial metastases was also defined as a poor
prognostic factor with a median survival of 39 days. Interestingly,
Table 2 Univariate analysis
No. HR (95% CI) P-value
RPA class (n¼98)
11 4 1
2 54 1.61 (0.84–3.09)
3 30 5.93 (2.88–12.21) o0.001
Time from diagnosis to brain
metastases (n¼95) (years)
o1.5 25 1
1.5–3 26 1.24 (0.71–2.19)
43 44 0.84 (0.51–1.39) 0.31
PD in brain on imaging prior to WBRT
(n¼92)
No 54 1
Yes 28 1.06 (0.65–1.71) 0.82
Meningeal disease (n¼95)
No 88 1
Yes 7 3.13 (1.41–6.95) 0.005
Number of brain metastases (n¼94)
11 8 1
2 15 0.97 (0.48–1.97)
X3 61 1.29 (0.74–2.25) 0.48
Number of ECM sites (n¼96)
01 9 1
1 20 1.38 (0.71–2.67)
2 29 2.2 (1.18–4.09)
3 16 2.11 (1.05–4.23)
4+ 12 5.89 (2.68–12.94) o0.001
ECM and response (n¼96)
None 19 1
SD 38 1.5 (0.91–2.66)
PD 39 2.31 (1.35–3.96) 0.009
Prior chemotherapy (n¼93)
No 47 1
Yes 46 1.32 (0.87–2.0) 0.2
Data were collected on 102 patients, but in all categories some data were missing.
The number of patients for whom data were available in each category is indicated in
parentheses (e.g. RPA class (n¼98)).
Table 3 Multivariate analysis
No. HR (95% CI) P-value
RPA class
11 3 1
2 42 1.31 (0.56–3.06)
3 26 3.78 (1.28–11.16) 0.004
PD in brain on imaging prior to WBRT
No 54 1
Yes 27 2.06 (1.19–3.59) 0.01
Meningeal disease
None 75 1
Yes 6 3.31 (1.27–8.61) 0.014
Number of ECM sites
01 8 1
1 16 0.68 (0.23–2.0)
2 22 1.63 (0.57–4.64)
3 14 1.37 (0.46–4.12)
4+ 11 4.13 (1.18–14.42) 0.012
Full data were available on all parameters for 81 patients for the purpose of
multivariate analysis.
Table 4 Prognostic index
a
Score Number HR
Median survival
(days)
2–4 17 1 138
5–6 16 1.2 80
7–8 24 2.2 42
9–10 14 9.6 18
11+ 10 14 15
aPrognostic index¼number of ECM sites+(2 RPA)+(2 if PD in brain on
imaging)+(4 if meningeal).
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metastases were deemed stable or progressive.
The data clearly demonstrate that patients in RPA class 1 and 2
should be considered for active treatment. Those in class 1 are
most likely to benefit from aggressive management and should be
considered for surgery, SRT, WBRT or cytotoxic chemotherapy (or
combinations of these modalities), depending on the clinical
picture. Now that this group of patients can be identified, it will be
important to design randomised clinical trials to determine the
optimal treatment approach for them. However, a greater
challenge lies in identifying those patients in class 2 who are
likely to benefit from WBRT and those who are not. By applying
the derived prognostic index, it can be seen that those in RPA class
2 with a score of 9 or greater (i.e. leptomeningeal disease, five ECM
sites or three ECM sites and PD in brain on imaging) have a
median survival of only 21 days and are unlikely to benefit from
WBRT. Therefore, future clinical trials in patients with brain
metastases from MMM should direct patients in RPA class 2 with a
prognostic score of 9 or more into studies of best supportive care.
Patients with RPA class 2 and a prognostic score less than 9 should
be considered for studies of WBRT with or without the addition of
cytotoxic chemotherapy or biological agents.
These data provide important insights into the outcome of
patients with brain metastases of MMM and demonstrate that it
is possible to predict therapeutic outcome and to design future
clinical studies on the basis of a number of simple clinical
parameters. In the first instance, the RTOG RPA classification
acts as an effective initial screen for patients who are likely to
succumb rapidly to their disease. Therefore, such patients (RPA
class 3 and 2 with a poor prognostic score) can be spared the
unnecessary side effects of ineffective palliative WBRT and
offered best supportive care alone. In contrast, patients in RPA
class 1 and 2 with a better prognostic score can be considered for
active therapeutic studies. By selecting and stratifying patients in
this way, it should be possible to examine the role of palliative
treatments in a more meaningful fashion than is currently
possible.
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Figure 3 Survival by prognostic group.
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